Cantor Fitzgerald Reiterates Overweight on Elevance Health, Maintains $600 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Sarah James has reiterated an Overweight rating on Elevance Health (NYSE:ELV) and maintained a $600 price target.
August 19, 2024 | 3:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating for Elevance Health, maintaining a $600 price target, indicating confidence in the company's performance.
The reiteration of an Overweight rating and a $600 price target by a reputable analyst suggests a positive outlook for Elevance Health. This could lead to increased investor confidence and potentially a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100